Literature DB >> 19297252

Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin.

Andreea Coca1, Kemp W Bundy, Bethany Marston, Jennifer Huggins, R John Looney.   

Abstract

Two patients presented at the University of Rochester Medical Center with a febrile illness, cytopenias, organ failure (liver failure or respiratory failure), and markedly elevated serum ferritin and sIL-2R. A diagnosis of probable macrophage activation syndrome was made. Both patients failed initial therapy with steroids and cyclosporine, either due to toxicity or lack of efficacy. Both patients responded dramatically to rabbit anti-thymocyte globulin (ATG).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19297252     DOI: 10.1016/j.clim.2009.02.005

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  16 in total

1.  Successful treatment of macrophage activation syndrome due to systemic onset juvenile idiopathic arthritis with antithymocyte globulin.

Authors:  Kubra Ozturk; Zelal Ekinci
Journal:  Rheumatol Int       Date:  2015-07-26       Impact factor: 2.631

2.  Adult-Onset Still's Disease and Macrophage-Activating Syndrome Progressing to Lymphoma: A Clinical Pathology Conference Held by the Division of Rheumatology at Hospital for Special Surgery.

Authors:  Bella Mehta; Shanthini Kasturi; Julie Teruya-Feldstein; Steven Horwitz; Anne R Bass; Doruk Erkan
Journal:  HSS J       Date:  2018-03-26

Review 3.  Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.

Authors:  Grant S Schulert; Alexei A Grom
Journal:  Annu Rev Med       Date:  2014-11-05       Impact factor: 13.739

Review 4.  Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.

Authors:  Lauren A Henderson; Randy Q Cron
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

Review 5.  Hyperferritinemia and inflammation.

Authors:  Kate F Kernan; Joseph A Carcillo
Journal:  Int Immunol       Date:  2017-11-01       Impact factor: 4.823

Review 6.  Macrophage activation syndrome: advances towards understanding pathogenesis.

Authors:  Alexei A Grom; Elizabeth D Mellins
Journal:  Curr Opin Rheumatol       Date:  2010-09       Impact factor: 5.006

Review 7.  Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis.

Authors:  Han-Qi Zhang; Si-Wei Yang; Yi-Cheng Fu; Ming-Cong Chen; Cheng-Hao Yang; Ming-Hua Yang; Xiao-Dan Liu; Qing-Nan He; Hua Jiang; Ming-Yi Zhao
Journal:  Immunol Res       Date:  2022-07-11       Impact factor: 4.505

Review 8.  CD163 and inflammation: biological, diagnostic, and therapeutic aspects.

Authors:  Anders Etzerodt; Søren K Moestrup
Journal:  Antioxid Redox Signal       Date:  2012-10-19       Impact factor: 8.401

Review 9.  Macrophage Activation Syndrome.

Authors:  Ethan S Sen; Sarah L N Clarke; Athimalaipet V Ramanan
Journal:  Indian J Pediatr       Date:  2015-09-24       Impact factor: 1.967

Review 10.  Macrophage activation syndrome and cytokine-directed therapies.

Authors:  Grant S Schulert; Alexei A Grom
Journal:  Best Pract Res Clin Rheumatol       Date:  2014-04       Impact factor: 4.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.